CN103209692A - 多发性硬化(ms)的新疗法 - Google Patents

多发性硬化(ms)的新疗法 Download PDF

Info

Publication number
CN103209692A
CN103209692A CN2011800529378A CN201180052937A CN103209692A CN 103209692 A CN103209692 A CN 103209692A CN 2011800529378 A CN2011800529378 A CN 2011800529378A CN 201180052937 A CN201180052937 A CN 201180052937A CN 103209692 A CN103209692 A CN 103209692A
Authority
CN
China
Prior art keywords
chemical compound
flurbiprofen
described chemical
coo
multiple sclerosis
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CN2011800529378A
Other languages
English (en)
Chinese (zh)
Inventor
艾尔姆加德·泰格德
歌德·盖斯灵格
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Fraunhofer Gesellschaft zur Foerderung der Angewandten Forschung eV
Original Assignee
Fraunhofer Gesellschaft zur Foerderung der Angewandten Forschung eV
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Fraunhofer Gesellschaft zur Foerderung der Angewandten Forschung eV filed Critical Fraunhofer Gesellschaft zur Foerderung der Angewandten Forschung eV
Publication of CN103209692A publication Critical patent/CN103209692A/zh
Pending legal-status Critical Current

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C53/00—Saturated compounds having only one carboxyl group bound to an acyclic carbon atom or hydrogen
    • C07C53/132—Saturated compounds having only one carboxyl group bound to an acyclic carbon atom or hydrogen containing rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/192—Carboxylic acids, e.g. valproic acid having aromatic groups, e.g. sulindac, 2-aryl-propionic acids, ethacrynic acid 
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Organic Chemistry (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Immunology (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychiatry (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)
CN2011800529378A 2010-11-03 2011-11-03 多发性硬化(ms)的新疗法 Pending CN103209692A (zh)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
GB1018519.7A GB2485169A (en) 2010-11-03 2010-11-03 (R)-flurbiprofen for use in the treatment of multiple sclerosis
GB1018519.7 2010-11-03
PCT/EP2011/069319 WO2012059541A1 (en) 2010-11-03 2011-11-03 Novel treatment of multiple sclerosis (ms)

Publications (1)

Publication Number Publication Date
CN103209692A true CN103209692A (zh) 2013-07-17

Family

ID=43401688

Family Applications (1)

Application Number Title Priority Date Filing Date
CN2011800529378A Pending CN103209692A (zh) 2010-11-03 2011-11-03 多发性硬化(ms)的新疗法

Country Status (10)

Country Link
US (1) US20130309199A1 (enExample)
EP (1) EP2635271A1 (enExample)
JP (1) JP5903438B2 (enExample)
KR (1) KR101877587B1 (enExample)
CN (1) CN103209692A (enExample)
BR (1) BR112013010883A2 (enExample)
CA (1) CA2816911C (enExample)
GB (1) GB2485169A (enExample)
RU (1) RU2595861C2 (enExample)
WO (1) WO2012059541A1 (enExample)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2022089598A1 (zh) * 2020-10-30 2022-05-05 杭州拉林智能科技有限公司 黄酮苷-有机胺类神经激动剂复盐化合物及其制备方法和应用

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2017080989A1 (en) 2015-11-09 2017-05-18 Fraunhofer-Gesellschaft zur Förderung der angewandten Forschung e.V. (r)-fluriprofen for the prevention and/or treatment of diabetes
US12097292B2 (en) 2016-08-28 2024-09-24 Mapi Pharma Ltd. Process for preparing microparticles containing glatiramer acetate
SMT202500136T1 (it) 2016-08-31 2025-05-12 Mapi Pharma Ltd Sistemi a deposito comprendenti glatiramer acetato
US11167003B2 (en) 2017-03-26 2021-11-09 Mapi Pharma Ltd. Methods for suppressing or alleviating primary or secondary progressive multiple sclerosis (PPMS or SPMS) using sustained release glatiramer depot systems
CA3082108A1 (en) 2017-11-14 2019-05-23 Merck Sharp & Dohme Corp. Novel substituted biaryl compounds as indoleamine 2,3-dioxygenase (ido) inhibitors
US11498904B2 (en) 2017-11-14 2022-11-15 Merck Sharp & Dohme Llc Substituted biaryl compounds as indoleamine 2,3-dioxygenase (IDO) inhibitors
EA035792B1 (ru) * 2018-06-21 2020-08-11 Государственное Научное Учреждение "Институт Биоорганической Химии Национальной Академии Наук Беларуси" Лекарственное средство пролонгированного действия для лечения рассеянного склероза (варианты)

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2008034244A1 (en) * 2006-09-21 2008-03-27 Waratah Pharmaceuticals Inc. The combination of a cyclohexanehexol and a nsaid for the treatment of neurodegenerative diseases
WO2008036733A2 (en) * 2006-09-19 2008-03-27 Myriad Genetics, Inc. Methods for treatment of vesicle transport disorders
WO2009083115A1 (de) * 2007-12-21 2009-07-09 Paz Arzneimittel-Entwicklungsgesellschaft Mbh Arzneimittel sowie deren herstellung und verwendung bei der behandlung von schmerzhaften neuropathien

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE19907895A1 (de) * 1999-02-24 2000-11-16 Paz Arzneimittelentwicklung Verwendung von R-Arylpropionsäuren zur Herstellung von Arzneimitteln zur Behandlung von Erkrankungen bei Mensch und Tier, welche durch die Hemmung der Aktivierung von NF-kB therapeutisch beeinflußt werden können
JP2006517925A (ja) * 2003-01-14 2006-08-03 メルク　エンド　カムパニー　インコーポレーテッド Ａβ４２低下薬としてのジェミナル二置換ＮＳＡＩＤ誘導体
US20090162421A1 (en) * 2007-12-21 2009-06-25 Paz Arzneimittel-Entwicklungsgesellschaft Mbh Drugs as well as their production and use in the treatment of pain-associated neuropathies
WO2011131661A1 (en) * 2010-04-21 2011-10-27 Chiesi Farmaceutici S.P.A. 1-(2-fluorobiphenyl-4-yl)-alkyl carboxylic acid derivatives for the therapy of transthyretin amyloidosis

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2008036733A2 (en) * 2006-09-19 2008-03-27 Myriad Genetics, Inc. Methods for treatment of vesicle transport disorders
WO2008034244A1 (en) * 2006-09-21 2008-03-27 Waratah Pharmaceuticals Inc. The combination of a cyclohexanehexol and a nsaid for the treatment of neurodegenerative diseases
WO2009083115A1 (de) * 2007-12-21 2009-07-09 Paz Arzneimittel-Entwicklungsgesellschaft Mbh Arzneimittel sowie deren herstellung und verwendung bei der behandlung von schmerzhaften neuropathien

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2022089598A1 (zh) * 2020-10-30 2022-05-05 杭州拉林智能科技有限公司 黄酮苷-有机胺类神经激动剂复盐化合物及其制备方法和应用

Also Published As

Publication number Publication date
WO2012059541A1 (en) 2012-05-10
RU2013125470A (ru) 2014-12-10
JP5903438B2 (ja) 2016-04-13
RU2595861C2 (ru) 2016-08-27
US20130309199A1 (en) 2013-11-21
EP2635271A1 (en) 2013-09-11
BR112013010883A2 (pt) 2016-09-13
GB201018519D0 (en) 2010-12-15
KR20140017494A (ko) 2014-02-11
CA2816911A1 (en) 2012-05-10
JP2014505015A (ja) 2014-02-27
KR101877587B1 (ko) 2018-07-11
CA2816911C (en) 2018-09-25
GB2485169A (en) 2012-05-09

Similar Documents

Publication Publication Date Title
CN103209692A (zh) 多发性硬化(ms)的新疗法
US10195170B2 (en) Methods for inhibiting expression of ASC, expression of NLRP3, and/or formation of NLRP3 inflammasome complex using diacerein or its analogs
KR102491426B1 (ko) 고용체 조성물
KR101567885B1 (ko) 고요산혈증 및 고요산혈증 관련 대사 장애를 치료하기 위한 방법 및 조성물
IL294736A (en) Preparations including 15-hydroxy-eicosapentaenoic acid and methods of using them
CN107308141B (zh) 石斛酚在制备预防和治疗动脉粥样硬化药物中的应用
WO2015105757A1 (en) Dimethyl fumarate for treating multiple sclerosis
CN101932316A (zh) 药物制剂及其制备和其在治疗疼痛相关的神经病中的应用
Kumar et al. Novel formulation approaches used for the management of osteoarthritis: A recent review
WO2013026772A1 (en) Flurbiprofen and related compounds for the treatment of skin diseases
US11850252B2 (en) Use of nor-ursodeoxycholic acid for reducing liver fat
JP2004002362A (ja) くしゃみ抑制組成物
RU2779839C2 (ru) Композиции твердых растворов и их применение при хроническом воспалении
Vergara et al. The Combination of Empagliflozin and Atrasentan on Top of RAS Blockade Ameliorates Cardiorenal Syndrome in the db/db Type 2 Diabetes Mouse Model: TH-PO178
Aalbers ACCORD LIPID study results strengthen guideline approach of adding fenofibrate to therapy of dyslipidaemic type 2 diabetic patients: drug trends in cardiology
WO2017080989A1 (en) (r)-fluriprofen for the prevention and/or treatment of diabetes
WO2021168518A1 (en) S1p receptor modulators
Park et al. KOREAN ROSUVASTATIN EFFECTIVENESS STUDY IN NONDIABETIC METABOLIC SYNDROME (KREST)
Paragh et al. ANIMAL MODEL FOR SIMULTANEOUS STUDY OF STATIN-EFFECTS AGAINST HYPERCHOLESTEROLEMIA AND TUMOR DEVELOPMENT
Singh et al. M1743 Amelioration of Citrobacter rodentium Colitis by Apoe-Mimetic Peptide COG112 by Inhibition of NF-κB
Funakoshi et al. A Novel NF-κB Inhibitor, DHMEQ, Ameliorates Inflammatory Colonic Injuries in Mice
Lin et al. M1745 Prevention of Colonic Fibrosis by Taurine in Rats With Colitis Induced by 2, 4, 6-Trinitrobenzene Sulphonic Acid
Brown et al. M1744 An Inhibitor of Light but not Lymphotoxin β Ameliorates Colonic GVHD Induced by Transfer of Dba/2j Bone Marrow and T Cells Into B6d2f1 Mice
Blom et al. Rosuvastatin reduces non-HDL-cholesterol and lipoprotein remnants in Fredrickson type III hyperlipoproteinaemia patients

Legal Events

Date Code Title Description
C06 Publication
PB01 Publication
C10 Entry into substantive examination
SE01 Entry into force of request for substantive examination
C02 Deemed withdrawal of patent application after publication (patent law 2001)
WD01 Invention patent application deemed withdrawn after publication

Application publication date: 20130717